Literature DB >> 19162226

Intracarotid propofol testing: a comparative study with amobarbital.

Mohamad A Mikati1, Georges Naasan, Hayssam Tarabay, Sarah El Yamen, Ahmad Baydoun, Youssef G Comair.   

Abstract

Twenty-five consecutive patients who underwent the Wada test using propofol as anesthetic were compared with 15 randomly selected patients who were tested using amobarbital. Time to verbal and nonverbal responses and time to motor power 3/5 did not differ between the two groups (P>0.05). The number of doses received by each patient and the percentage of patients needing more than one dose were significantly greater in the propofol group (P<0.005). Only one patient developed confusion, combativeness, and agitation. Despite the need for multiple doses, our patients had no residual drowsiness within 10 to 15 minutes of the propofol injection. This allowed us to perform the test on both sides on the same day separated only by 45 minutes. Propofol is an effective alternative to amobarbital in the Wada test, and may be used successfully in multiple repeated injections within the same test without significant residual sedation or significant adverse effects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19162226     DOI: 10.1016/j.yebeh.2008.12.023

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  4 in total

1.  Quantitative EEG is an objective, sensitive, and reliable indicator of transient anesthetic effects during Wada tests.

Authors:  Bin Tu; Nadege J Assassi; Carl W Bazil; Marla J Hamberger; Lawrence J Hirsch
Journal:  J Clin Neurophysiol       Date:  2015-04       Impact factor: 2.177

2.  Feasibility of the superselective test with propofol for determining eloquent brain regions in the endovascular treatment of arteriovenous malformations.

Authors:  José A Jordán González; Juan Carlos Llibre Guerra; José A Prince López; Frank Vázquez Luna; Raúl Marino Rodríguez Ramos; José Carlos Ugarte Suárez
Journal:  Interv Neuroradiol       Date:  2013-09-26       Impact factor: 1.610

3.  Tolerability of propofol in Wada testing.

Authors:  Faisal A Alsallom; Shobhit Sinha; Fahmi M Alsenani; Fawziah A Bamogaddam; Saeed H Wahass; Aurora B Canillo; Khurram A Siddiqui
Journal:  Neurosciences (Riyadh)       Date:  2014-07       Impact factor: 0.906

4.  Experience of adverse events with cerebral propofol testing in patients with drug resistant epilepsy.

Authors:  Marta Szantroch; Aleksandra Bala; Andrzej Rysz; Jarosław Żyłkowski; Andrzej Marchel
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.